Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

Authors: Gupta, Neeraj, Hanley, Michael J., Venkatakrishnan, Karthik, Bessudo, Alberto, Rasco, Drew W., Sharma, Sunil, O'Neil, Bert H., Wang, Bingxia, Liu, Guohui, Ke, Alice, Patel, Chirag, Rowland Yeo, Karen, Xia, Cindy, Zhang, Xiaoquan, Esseltine, Dixie‐Lee, Nemunaitis, John

Source: Journal of clinical pharmacology. 58(2):180-192

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100150095179.0x000001&indx=1&recIds=ETOCvdc_100150095179.0x000001

A phase 1, first-in-human, dose-escalation and expansion study of FX-909 in patients with advanced solid malignancies, including advanced urothelial carcinoma.

Authors: Iyer, Gopa, Gao, Xin, Rasco, Drew W., Milowsky, Matthew I., Garmezy, Benjamin, Rodriguez Rivera, Ildefonso I, Tepper, Jennifer, Moles, Melissa Ann, Gjini, Evisa, Bowden, Michaela, Meyers, Michael L., Bellmunt, Joaquim, Galsky, Matt D.

Source: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pTPS709-TPS709, 193p

First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Authors: Rathkopf, Dana E., Patel, Manish R., Choudhury, Atish Dipankar, Rasco, Drew W., Lakhani, Nehal J., Hawley, Jessica E., Aparicio, Ana, Narayan, Vivek, Srinivas, Sandy, Runcie, Karie, Emamekhoo, Hamid, Reichert, Zachery R, Carducci, Michael Anthony, Wells, Amber L., Liu, Can, Kandimalla, Raju, Wu, Jiaju, Nguyen, Marie Huong, Pourdehnad, Michael, Armstrong, Andrew J.

Source: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p134-134, 235p

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.

Authors: Rasco, Drew W.¹ (AUTHOR), Medina, Theresa² (AUTHOR), Corrie, Pippa³ (AUTHOR), Pavlick, Anna C.⁴ (AUTHOR), Middleton, Mark R.⁵ (AUTHOR), Lorigan, Paul⁶ (AUTHOR), Hebert, Chris⁷ (AUTHOR), Plummer, Ruth⁸ (AUTHOR), Larkin, James⁹ (AUTHOR), Agarwala, Sanjiv S.¹⁰ (AUTHOR), Daud, Adil I.¹¹ (AUTHOR), Qiu, Jiaheng¹² (AUTHOR), Bozon, Viviana¹³ (AUTHOR), Kneissl, Michelle¹³ (AUTHOR), Barry, Elly¹² (AUTHOR) elly.barry@dayonebio.com, Olszanski, Anthony J.¹⁴ (AUTHOR)

Source: Cancer Chemotherapy & Pharmacology. Jul2023, Vol. 92 Issue 1, p15-28. 14p.

Subject Terms: *IPILIMUMAB, *MELANOMA, *IMPRINTED polymers, *EXENATIDE, *SMALL molecules, *ANTINEOPLASTIC agents, *METASTASIS, *TUMORS

Predictors and Impact of Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer in the United States: Real-World Considerations for Maintenance Therapy

Authors: Gerber, David E., Rasco, Drew W., Le, Phat, Yan, Jingsheng, Dowell, Jonathan E., Xie, Yang

Source: In Journal of Thoracic Oncology February 2011 6(2):365-371

Association between biomarkers and clinical outcomes of lenvatinib + pembrolizumab in advanced renal cell carcinoma (RCC): Results from Study 111/KEYNOTE-146.

Authors: Lee, Chung-Han, Rasco, Drew W., Rao, Arpit, Taylor, Matthew H., Hsieh, James J, Pinto, Alvaro, Vogelzang, Nicholas J., Cao, Z. Alexander, Suttner, Leah, Loboda, Andrey, Vajdi, Amir, Predoiu, Raluca Andreia, Nebozhyn, Michael, Lunceford, Jared, Perini, Rodolfo F., Matsui, Junji, Minoshima, Yukinori, Dutcus, Corina E., Dutta, Lea, Motzer, Robert J.

Source: Journal of clinical oncology. 40(6 suppl):375-375

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100152991005.0x000001&indx=1&recIds=ETOCvdc_100152991005.0x000001

Randomized phase II trial of two different nutritional approaches for patients receiving treatment for their advanced pancreatic cancer.

Authors: Hanna, Diana L., Jameson, Gayle S., Rasco, Drew W., Alistar, Angela Tatiana, Frank, Richard C., El-Khoueiry, Anthony B., Wiedmeier, Julia, Roberts, Caroline, Fell, Brandon, Hallberg, Sarah, Roe, Denise, Cridebring, Derek, Rabinowitz, Joshua D, Gately, Stephen, Von Hoff, Daniel D.

Source: Journal of clinical oncology. 40(4 suppl):TPS637-TPS637

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100152973037.0x000001&indx=1&recIds=ETOCvdc_100152973037.0x000001

A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers.

Authors: Harding, James J., Hofheinz, Ralf-Dieter, Elez, Elena, Kuboki, Yasutoshi, Rasco, Drew W., Cecchini, Michael, Shen, Lin, Dowling, Elizabeth, Archuadze, Shorena, de Pereira, Bruna Andrade, Pant, Shubham

Source: Journal of clinical oncology. 40(4 suppl):TPS222-TPS222

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100152958952.0x000001&indx=1&recIds=ETOCvdc_100152958952.0x000001

Looking Beyond Surveillance, Epidemiology, and End Results: Patterns of Chemotherapy Administration for Advanced Non-small Cell Lung Cancer in a Contemporary, Diverse Population

Authors: Rasco, Drew W., Yan, Jingsheng, Xie, Yang, Dowell, Jonathan E., Gerber, David E.

Source: In Journal of Thoracic Oncology October 2010 5(10):1529-1535

A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors.

Authors: Patnaik, Amita, Hamilton, Erika, Xing, Yan, Rasco, Drew W., Smith, Lon, Lee, Ya-Li, Fang, Steven, Wei, Jiao, Hui, Ai-Min

Source: Cancers; Oct2022, Vol. 14 Issue 20, p4996-N.PAG, 14p

Subject Terms: RESEARCH, GENETIC mutation, ANTINEOPLASTIC agents, TUMOR classification, DESCRIPTIVE statistics, TUMORS, DATA analysis software

Geographic Terms: UNITED States

Phase 1/2 first-in-human (FIH) study of CPI-0209, a novel small molecule inhibitor of enhancer of zeste homolog 2 (EZH2) in patients with advanced tumors.

Authors: Lakhani, Nehal J., Gutierrez, Martin, Duska, Linda R., Do, Khanh Tu, Sharma, Manish, Gandhi, Leena, Papadopoulos, Kyriakos P., Truong, Jennifer, Fan, Xiaolin, Lee, Ji Hyun, Bobba, Suresh, Rippley, Ronda, Wu, Rentian, Cui, Jike, Sun, Kaiming, Wang, Jing Y., Trojer, Patrick, Rasco, Drew W.

Source: Journal of clinical oncology. 39(15 suppl):3104-3104

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173190121.0x000001&indx=1&recIds=ETOCvdc_100173190121.0x000001

Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors.

Authors: Sharma, Manish, Carvajal, Richard D., Hanna, Glenn J., Li, Bob T., Moore, Kathleen N., Pegram, Mark D., Rasco, Drew W., Spira, Alexander I., Alonso, Michael, Fang, Liang, Husain, Amreen, Perez, Edith A., Dumbrava, Ecaterina Elena

Source: Journal of clinical oncology. 39(15 suppl):2549-2549

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173185866.0x000001&indx=1&recIds=ETOCvdc_100173185866.0x000001

BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7/8) agonist, in combination with pembrolizumab in advanced solid tumors: Phase 1 safety and efficacy results.

Authors: Patel, Manish R., Tolcher, Anthony W., Rasco, Drew W., Johnson, Melissa Lynne, Alistar, Angela Tatiana, Li, Lixin, Chung, Alexander H., Andtbacka, Robert H.I.

Source: Journal of clinical oncology. 39(15 suppl):2512-2512

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173185428.0x000001&indx=1&recIds=ETOCvdc_100173185428.0x000001

Preliminary clinical and biologic results of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab, in advanced solid tumors (KEYNOTE A36).

Authors: Park, Haeseong, Bendell, Johanna C., Messersmith, Wells A., Rasco, Drew W., De Bono, Johann S., Strickler, John H., Zhou, Lei, Carter, Laura L, Bruey, Jean-Marie, Li, Jack, Raghupathi, Kartik, Dupont, Jakob, Chaney, Marya F., Park, Wungki

Source: Journal of clinical oncology. 39(15 suppl):2505-2505

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173185363.0x000001&indx=1&recIds=ETOCvdc_100173185363.0x000001

COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716).

Authors: Vaena, Daniel A., Fleming, Gini F., Chmielowski, Bartosz, Sharma, Manish, Hamilton, Erika P., Sullivan, Ryan J., Shepard, Dale Randall, Papadopoulos, Kyriakos P., Patnaik, Amita, ElNaggar, Adam, Adewoye, Adeboye H., Smith, Robina, Lim, Emerson A., Dumbrava, Ecaterina Elena, Rasco, Drew W.

Source: Journal of clinical oncology. 39(15 suppl):2504-2504

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173185341.0x000001&indx=1&recIds=ETOCvdc_100173185341.0x000001

Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.

Authors: LoRusso, Patricia, Ratain, Mark J., Doi, Toshihiko, Rasco, Drew W., de Jonge, Maja J. A., Moreno, Victor, Carneiro, Benedito A., Devriese, Lot A., Petrich, Adam, Modi, Dimple, Morgan-Lappe, Susan, Nuthalapati, Silpa, Motwani, Monica, Dunbar, Martin, Glasgow, Jaimee, Medeiros, Bruno C., Calvo, Emiliano

Source: Investigational New Drugs; Aug2022, Vol. 40 Issue 4, p762-772, 11p

Subject Terms: THERAPEUTIC use of antineoplastic agents, TREATMENT effectiveness, TUMORS, EVALUATION

Integrating Metastasectomy in the Management of Advanced Urological Malignancies—Where are we in 2005?

Authors: Rasco, Drew W., Assikis, Vasily, Marshall, Fray

Source: In The Journal of Urology 2006 176(5):1921-1926

Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.

Authors: Patnaik, Amita, Gadgeel, Shirish, Papadopoulos, Kyriakos P., Rasco, Drew W., Haas, Naomi B., Der-Torossian, Hirak, Faltaos, Demiana, Potvin, Diane, Tassell, Vanessa, Tawashi, Manal, Chao, Richard, O'Dwyer, Peter J.

Source: Targeted Oncology; Mar2022, Vol. 17 Issue 2, p125-138, 14p

Subject Terms: THERAPEUTIC use of antineoplastic agents, DRUG efficacy, RESEARCH, CLINICAL trials, ERLOTINIB, CELL receptors, CANCER patients, DOCETAXEL, PROTEIN-tyrosine kinases, TUMORS, EVALUATION

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial.

Authors: Patnaik, Amita, Weiss, Glen J., Rasco, Drew W., Blaydorn, Lisa, Mirabella, Amy, Beeram, Murali, Guo, Wei, Lu, Sharon, Danaee, Hadi, McEachern, Kristen, Im, Ellie, Sachdev, Jasgit C.

Source: Cancer Chemotherapy & Pharmacology; Jan2022, Vol. 89 Issue 1, p93-103, 11p

Subject Terms: PROGRAMMED cell death 1 receptors, ANTINEOPLASTIC agents, PHARMACOKINETICS

This result is not displayed to guests.
Login for full access.